Navigation Links
Clinical trial for new tuberculosis vaccine
Date:9/11/2008

This release is available in German.

Since Monday of this week, the new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.

The scientific basis for this was laid down by the team working with Stefan H.E. Kaufmann, Director at the Max Planck Institute for Infection Biology. "The BCG tuberculosis vaccine, which was developed by French researchers, is the most frequently administered live vaccine in the world," says Kaufmann. However, BCG (short for the bacterium Bacillus Calmette-Gurind) is now frequently ineffective. The immunologist continues: "BCG has become a blunt weapon. We wanted to use genetic engineering to sharpen it so that, rather than hiding from the human immune system, it would stimulate it as much as possible."

To do this, the researchers inserted a gene into the vaccine bacteria. Leander Grode, who at the time was a member of Stefan H.E. Kaufmann's staff and is today heads a project at Vakzine Projekt Management GmbH (VPM), describes the process: "The vaccine bacteria are taken up by the scavenger cells of the human immune system and end up in their digestion chambers. The genetically engineered modification allows them to escape from the chambers and arm the immune system against the tuberculosis pathogens."

The scientific studies were initially undertaken at the Max Planck Institute for Infection Biology. In 2004, the vaccine was licensed to the Hanover-based VPN, which expedited the clinical study. Thus far, the new vaccine has proven to be extremely effective and safe in animal models. "We now need to prove that it has the same positive
'/>"/>

Contact: Prof. Stefan H.E. Kaufmann
kaufmann@mpiib-berlin.mpg.de
49-302-846-0500
Max-Planck-Gesellschaft
Source:Eurekalert  

Page: 1 2

Related biology news :

1. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
2. New study spotlights National Institutes of Health grant outcomes for clinical research
3. NCI grant launches clinical trials for colon cancer screening
4. Florida researchers receive JDRF Excellence in Clinical Research Award
5. A nutritional supplement could improve the clinical situation of ICU patients
6. NIH expands national consortium dedicated to transforming clinical and translational research
7. Peter J. McGuire, MB BCh, is awarded the 2008-2009 Genzyme/ACMGF Clinical Genetics Fellowship
8. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
9. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
10. NHLBI issues first US von Willebrand Disease clinical practice guidelines
11. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial for new tuberculosis vaccine
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... , We encounter valves every day, whether in ... bicycle tire tube. Valves are also present in the world ... Stoddart and Jeffrey I. Zink at the University of California, ... journal Angewandte Chemie, the scientists reveal what is special about ...
... study of how individual wandering albatrosses find food shows that ... birds can pick up a scent from several miles away, ... first time anyone has looked at the odor-tracking behavior of ... Nevitt, professor of neurobiology, physiology and behavior at UC Davis ...
... Ore. March 6, 2008. Forests can serve society ... and wildlife, and recreational opportunities, for example. Management ... of the USDA Forest Service. In May 2007, ... Alaska, for silviculturists, forest practitioners, and researchers designed ...
Cached Biology News:Skewered pumpkins 2Wandering albatrosses follow their nose 2
(Date:7/29/2015)... -- Research and Markets ( ... "Global Biosimilars Market, 2015 - 2025" ... Biosimilars Market, 2015 - 2025, report provides an ... With the blockbuster biologics losing patent protection and ... being viewed as viable substitutes to the highly ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead ... to protect the Orange County, Texas area from future storm surge flooding, such ... in determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic ...
Breaking Biology Technology:Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2
... Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted ... General Merrill A. McPeak to its Board of Directors. ... Air Force and was USAF chief of staff from ... of 7 members, including 5 independent directors. ...
... 20, 2011)A consortium led by scientists at the University of ... detailed genetic map. A genetic map specifies the ... egg where the DNA from the mother and father has ... The biological process whereby this reshuffling occurs is known as ...
... ® , a leading clinical stage biotechnology company ... that develops proprietary stem cell and tissue engineering ... of Development,s Third Frontier Commission awarded a $1 ... and Commercialization of Hematopoietic Stem Cell Expansion for ...
Cached Biology Technology:Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors 2Researchers create the world's most advanced genetic map 2Researchers create the world's most advanced genetic map 3Arteriocyte Receives $1 Million Award From Ohio Third Frontier Program to Advance Its NANEX™ Technology Toward Clinical Use 2